1. Home
  2. CRBP vs ESSA Comparison

CRBP vs ESSA Comparison

Compare CRBP & ESSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRBP
  • ESSA
  • Stock Information
  • Founded
  • CRBP 2009
  • ESSA 1916
  • Country
  • CRBP United States
  • ESSA United States
  • Employees
  • CRBP N/A
  • ESSA N/A
  • Industry
  • CRBP Biotechnology: Pharmaceutical Preparations
  • ESSA Banks
  • Sector
  • CRBP Health Care
  • ESSA Finance
  • Exchange
  • CRBP Nasdaq
  • ESSA Nasdaq
  • Market Cap
  • CRBP 227.3M
  • ESSA 192.5M
  • IPO Year
  • CRBP N/A
  • ESSA N/A
  • Fundamental
  • Price
  • CRBP $16.73
  • ESSA $20.15
  • Analyst Decision
  • CRBP Strong Buy
  • ESSA
  • Analyst Count
  • CRBP 7
  • ESSA 0
  • Target Price
  • CRBP $65.86
  • ESSA N/A
  • AVG Volume (30 Days)
  • CRBP 346.4K
  • ESSA 12.8K
  • Earning Date
  • CRBP 11-07-2024
  • ESSA 10-23-2024
  • Dividend Yield
  • CRBP N/A
  • ESSA 3.04%
  • EPS Growth
  • CRBP N/A
  • ESSA N/A
  • EPS
  • CRBP N/A
  • ESSA 1.81
  • Revenue
  • CRBP N/A
  • ESSA $68,480,000.00
  • Revenue This Year
  • CRBP N/A
  • ESSA N/A
  • Revenue Next Year
  • CRBP N/A
  • ESSA $6.92
  • P/E Ratio
  • CRBP N/A
  • ESSA $11.10
  • Revenue Growth
  • CRBP N/A
  • ESSA N/A
  • 52 Week Low
  • CRBP $4.00
  • ESSA $15.29
  • 52 Week High
  • CRBP $61.90
  • ESSA $21.50
  • Technical
  • Relative Strength Index (RSI)
  • CRBP 37.25
  • ESSA 55.80
  • Support Level
  • CRBP $15.65
  • ESSA $19.35
  • Resistance Level
  • CRBP $17.18
  • ESSA $20.33
  • Average True Range (ATR)
  • CRBP 1.26
  • ESSA 0.64
  • MACD
  • CRBP 0.35
  • ESSA 0.01
  • Stochastic Oscillator
  • CRBP 21.09
  • ESSA 52.46

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About ESSA ESSA Bancorp Inc.

ESSA Bancorp Inc is a holding company, engaged in accepting deposits from the general public and investing those deposits, together with funds generated from operations and borrowings, in residential first mortgage loans (including construction mortgage loans), commercial real estate loans, home equity loans and lines of credit and commercial and industrial loans. The company offers a variety of deposit accounts, including checking, savings and certificates of deposit. The company also offers asset management and trust services and investment services. The company also offers insurance benefit consulting services through its wholly-owned subsidiary, ESSA Advisory Services, LLC.

Share on Social Networks: